Details:
ONCOFID®-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
Lead Product(s): Paclitaxel
Therapeutic Area: Oncology Product Name: Oncofid-P
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 26, 2021
Details:
The decision is based upon Janssen's review of all available cusatuzumab data and in consideration of the evolving standard of care for the treatment of acute myeloid leukemia.
Lead Product(s): Cusatuzumab,Azacitidine
Therapeutic Area: Oncology Product Name: JNJ-74494550
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Argenx
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination June 07, 2021
Details:
Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally-advanced, not metastatic nonmelanoma skin cancer. Patients enrolled in the study will be treated with intralesional injections of NidlegyTM.
Lead Product(s): Bifikafusp alfa,Onfekafusp alfa
Therapeutic Area: Oncology Product Name: Nidlegy
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2020